Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 8/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
| ▸ | GNPAT | O15228 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4627107 | 0.88 | NOD1 (0.62) | NOD1SLC6A5MEN1FAAHMAPK1 | |
| SCHEMBL15623817 | 0.87 | NOD1 (0.61) | NOD1SLC6A5GNPATMEN1FAAH | |
| SCHEMBL9828089 | 0.86 | NOD1 (0.70) | NOD1SLC6A5MEN1FAAHMAPK1 | |
| SCHEMBL12655871 | 0.85 | GNPAT (0.56) | NOD1GNPATPOLB | |
| SCHEMBL9651941 | 0.85 | MME (0.51) | NOD1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL21314174 | 0.85 | MME (0.51) | NOD1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL28378530 | 0.85 | NOD1 (0.59) | NOD1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL5821359 | 0.85 | MME (0.51) | NOD1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL20225680 | 0.84 | NOD1 (0.73) | NOD1SLC6A5MEN1FAAHMAPK1 | |
| SCHEMBL22262078 | 0.84 | NOD1 (0.73) | NOD1SLC6A5MEN1FAAHMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059844-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-03-07 | — | — | US | disclosed |
| US-20130059844-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-03-07 | — | — | US | disclosed |
| US-20130059844-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-03-07 | — | — | US | disclosed |
| EP-2295436-A1 | 2-Phenyl-subsitituted Imidazotriazinones as Phosphodiesterase V inhibitors | Bayer Schering Pharma AG (DE) | 2011-03-16 | — | — | EP | disclosed |
| US-20110009367-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20110009367-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-13 | — | — | US | disclosed |
| US-7704999-B2 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-27 | — | — | US | disclosed |
| US-7704999-B2 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-27 | — | — | US | disclosed |
| US-7704999-B2 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-27 | — | — | US | disclosed |
| US-7696206-B2 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-13 | — | — | US | disclosed |
| CN-1234708-C | Novel imidazotriazinones and the use thereof | BAYER AG (DE) | 2006-01-04 | — | — | CN | disclosed |
| US-20050267112-A1 | Novel imidazotriazinones and the use thereof | BAYER AKTIENGESELLSCHAFT (US) | 2005-12-01 | — | — | US | disclosed |
| US-6890922-B2 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | BAYER HEALTHCARE AG (DE) | 2005-05-10 | — | — | US | disclosed |
| US-6878708-B2 | Imidazotriazinones and the use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2005-04-12 | — | — | US | disclosed |
| US-20050070541-A1 | 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2005-03-31 | — | — | US | disclosed |
| US-20040097498-A1 | Novel imidazotriazinones and the use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2004-05-20 | — | — | US | disclosed |
| US-20040067945-A1 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2004-04-08 | — | — | US | disclosed |
| US-6566360-B1 | Administering 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position for therapy of hypertrophy of the prostate, incontinence or female sexual dysfunction in mammals | BAYER AKTIENGESELLSCHAFT (DE) | 2003-05-20 | — | — | US | disclosed |
| CN-1407986-A | Novel imidazotriazinones and the use thereof | BAYER AG (DE) | 2003-04-02 | — | — | CN | disclosed |
| US-6362178-B1 | TREATMENT OF CARDIOVASCULAR DIORDERS, CEREBROVASCULAR DISORDERS, UROGENITAL DISORDERS AND ERECTILE DYSFUNCTION | BAYER AKTIENGESELLSCHAFT (DE) | 2002-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097498-A1 | Novel imidazotriazinones and the use thereof | CYP4F3, CYP4F2, CYP3A7 | NOD1 2843/4885HDAC3 2177/4885HDAC1 1988/4885 |
| US-20110009367-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE2A | NOD1 2143/4885HDAC3 2716/4885HDAC1 3619/4885 |
| US-20130059844-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE2A | NOD1 2143/4885HDAC3 2716/4885HDAC1 3619/4885 |
| US-20050070541-A1 | 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | PDE3B, PDE3A, PDE2A | NOD1 2143/4885HDAC3 2716/4885HDAC1 3619/4885 |
| US-20050267112-A1 | Novel imidazotriazinones and the use thereof | CYP3A7, CYP4F2, CYP4F3 | NOD1 3147/4885HDAC3 2287/4885HDAC1 2561/4885 |
| US-20040067945-A1 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | PDE3B, PDE3A, PDE2A | NOD1 2143/4885HDAC3 2716/4885HDAC1 3619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.